Chemotherapy-Induced Peripheral Neuropathy (CIPN): Difference between revisions

No edit summary
No edit summary
Line 5: Line 5:
</div>  
</div>  
== Introduction ==
== Introduction ==
Chemotherapy-induced peripheral neuropathy (CIPN) commonly occurs as an adverse event following chemotherapy.CIPN can  have an effect on the sensory, motor and/or autonomic nerves<ref name=":0">Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncology and therapy. 2021 Dec 1:1-66.Available:https://pubmed.ncbi.nlm.nih.gov/33490836/ (accessed 18.8.2023)</ref>.  
Chemotherapy-induced peripheral [[Neuropathies|neuropathy]] (CIPN) commonly occurs as an adverse event following chemotherapy.CIPN can  have an effect on the sensory, motor and/or autonomic nerves<ref name=":0">Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncology and therapy. 2021 Dec 1:1-66.Available:https://pubmed.ncbi.nlm.nih.gov/33490836/ (accessed 18.8.2023)</ref>.  


Currently there is no gold standard for diagnosis, no proven ways to lessen or stop this condition and treatment strategies need be addressed.<ref name=":0" />
Currently there is no gold standard for diagnosis, no proven ways to lessen or stop this condition and treatment strategies need be addressed.<ref name=":0" />
Line 12: Line 12:


Physiotherapy, in the form of exercise therapy, has been shown to have a role in reducing symptoms in CIPN<ref>Jesson T, Runge N, Schmid AB. [https://pubmed.ncbi.nlm.nih.gov/33490836/ Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety.] Pain Reports. 2020 Sep;5(5).Available: https://pubmed.ncbi.nlm.nih.gov/33490836/<nowiki/>(accessed 18.8.2023)</ref>.
Physiotherapy, in the form of exercise therapy, has been shown to have a role in reducing symptoms in CIPN<ref>Jesson T, Runge N, Schmid AB. [https://pubmed.ncbi.nlm.nih.gov/33490836/ Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety.] Pain Reports. 2020 Sep;5(5).Available: https://pubmed.ncbi.nlm.nih.gov/33490836/<nowiki/>(accessed 18.8.2023)</ref>.
== Risk Factors ==
Include: Agent used, cumulative dose, how many treatment cycles and its duration, genetic susceptibility, age, any existing nerve damage, severity of acute symptom, chronic alcohol consumption.<ref name=":0" />


== Treatment ==
== Treatment ==
Pharmacological: Pharmacological treatment for peripheral neuropathic pain is not very effective and also may have serious harmful consequences<ref>Jesson T, Runge N, Schmid AB. [https://pubmed.ncbi.nlm.nih.gov/33490836/ Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety.] Pain Reports. 2020 Sep;5(5).Available:https://pubmed.ncbi.nlm.nih.gov/33490836/ (accessed 19.8.2023)</ref>. Treatment option for symptoms include:
Pharmacological: Pharmacological treatment for peripheral neuropathic [[Pain Medications|pain]] is not very effective and also may have serious harmful consequences<ref>Jesson T, Runge N, Schmid AB. [https://pubmed.ncbi.nlm.nih.gov/33490836/ Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety.] Pain Reports. 2020 Sep;5(5).Available:https://pubmed.ncbi.nlm.nih.gov/33490836/ (accessed 19.8.2023)</ref>. Treatment option for symptoms include:


* Steroids, to lessen inflammation
* [[Corticosteroid Medication|Steroids]], to lessen inflammation
* Topical anesthetics  
* Topical anesthetics  
* Antiseizure medications, which can help relieve nerve pain
* Antiseizure medications, which can help relieve nerve pain
* Opioids
* [[Opioids]]
* AntidepressantsNon pharmacological:  
* Antidepressants
 
Non pharmacological:
* Transcutaneous electrical nerve stimulation
* [[Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation]]
* Physical therapy
* Physical therapy
* Occupational therapy
* Occupational therapy
Line 30: Line 33:
* Suggest strongly that duloxetine (a serotonin–norepinephrine reuptake inhibitor) is the only currently recommended treatment.  
* Suggest strongly that duloxetine (a serotonin–norepinephrine reuptake inhibitor) is the only currently recommended treatment.  


* No recommendations for treatment of CIPN in regards to exercise therapy, acupuncture, scrambler therapy, gabapentin, pregabalin, topical gel treatment (containing baclofen/amitriptyline plus/minus ketamine), tricyclic antidepressants or oral cannabinoids.<ref name=":0" />
* No recommendations for treatment of CIPN in regards to exercise therapy, [[acupuncture]], scrambler therapy, gabapentin, pregabalin, topical gel treatment (containing baclofen/amitriptyline plus/minus ketamine), tricyclic antidepressants or oral cannabinoids.<ref name=":0" />


== Resources  ==
== Resources  ==
Line 43: Line 46:


<references />
<references />
[[Category:Neuropathy]]
[[Category:Pain]]

Revision as of 03:08, 19 August 2023

Original Editor - Lucinda hampton

Top Contributors - Lucinda hampton and Mason Trauger  

Introduction[edit | edit source]

Chemotherapy-induced peripheral neuropathy (CIPN) commonly occurs as an adverse event following chemotherapy.CIPN can have an effect on the sensory, motor and/or autonomic nerves[1].

Currently there is no gold standard for diagnosis, no proven ways to lessen or stop this condition and treatment strategies need be addressed.[1]

CIPN regularly impacts chemotherapy, occasionally requiring the dose to be reduced or treatment ceased, effecting survival. Around 30% of patients will still have CIPN a year, or more post chemotherapy[2].

Physiotherapy, in the form of exercise therapy, has been shown to have a role in reducing symptoms in CIPN[3].

Risk Factors[edit | edit source]

Include: Agent used, cumulative dose, how many treatment cycles and its duration, genetic susceptibility, age, any existing nerve damage, severity of acute symptom, chronic alcohol consumption.[1]

Treatment[edit | edit source]

Pharmacological: Pharmacological treatment for peripheral neuropathic pain is not very effective and also may have serious harmful consequences[4]. Treatment option for symptoms include:

  • Steroids, to lessen inflammation
  • Topical anesthetics
  • Antiseizure medications, which can help relieve nerve pain
  • Opioids
  • Antidepressants

Non pharmacological:

Note. Recently published American Society of Clinical Oncology (ASCO) guidelines

  • Suggest strongly that duloxetine (a serotonin–norepinephrine reuptake inhibitor) is the only currently recommended treatment.
  • No recommendations for treatment of CIPN in regards to exercise therapy, acupuncture, scrambler therapy, gabapentin, pregabalin, topical gel treatment (containing baclofen/amitriptyline plus/minus ketamine), tricyclic antidepressants or oral cannabinoids.[1]

Resources[edit | edit source]

  • bulleted list
  • x

or

  1. numbered list
  2. x

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncology and therapy. 2021 Dec 1:1-66.Available:https://pubmed.ncbi.nlm.nih.gov/33490836/ (accessed 18.8.2023)
  2. Colvin LA. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now?. Pain. 2019 May;160(Suppl 1):S1.Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499732/ (accessed 19.8.2023)
  3. Jesson T, Runge N, Schmid AB. Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety. Pain Reports. 2020 Sep;5(5).Available: https://pubmed.ncbi.nlm.nih.gov/33490836/(accessed 18.8.2023)
  4. Jesson T, Runge N, Schmid AB. Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety. Pain Reports. 2020 Sep;5(5).Available:https://pubmed.ncbi.nlm.nih.gov/33490836/ (accessed 19.8.2023)